Industry Bodies Warn Against Switching Among Biosimilars
Executive Summary
EFPIA, the EBE and the IFPMA have issued a joint position paper in which they address a number of issues relating to biosimilars, including a caution against switching patients from one biosimilar of a reference drug to another.
You may also be interested in...
EU’s CHMP Expected To OK Another Biosimilar Humira
The European Medicines Agency’s CHMP is expected to give the green light to Samsung Bioepis’ biosimilar version of AbbVie’s anti-TNF-alpha Humira on June 23. Numerous other biosimilar developers have biosimilar adalimumabs under development in a bid to break into the $16bn market for the world’s top-selling drug.
EU’s CHMP Expected To OK Another Biosimilar Humira
The European Medicines Agency’s CHMP is expected to give the green light to Samsung Bioepis’ biosimilar version of AbbVie’s anti-TNF-alpha Humira on June 23. Numerous other biosimilar developers have biosimilar adalimumabs under development in a bid to break into the $16bn market for the world’s top-selling drug.
‘Non-Medical Switching’ Claim Riles Europe’s Biosimilars Industry
Two patient advocacy groups have said that a number of issues surrounding biosimilar switching, patient consent and traceability remain to be addressed in Europe, despite growing support for biosimilar use from physician bodies and clinical studies. But the European biosimilars industry has dismissed these concerns, saying that biosimilar medicines will significantly improve access to biologics patients while contributing to the sustainability of pharmaceutical budgets.